Pancreatic Cancer Research

ResearcherSecond Hospital of Shandong UniversityActive in the last 2 years

Jianxin Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8165-1371; OpenAlex author ID A5100413539. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2014: 2 papers · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: none · 2024: 1 paper

Papers 9

  1. Clinicopathological Characteristics, Prognosis, and Correlated Tumor Cell Function of Tropomodulin-3 in Pancreatic Adenocarcinoma. Co-author DOI 10.2174/1386207326666230810142646↗
  2. SLCO4A1-AS1 mediates pancreatic cancer development via miR-4673/KIF21B axis. Co-author DOI 10.1515/med-2022-0418↗
  3. Corrigendum to "Krüppel-like factor 9 suppressed tumorigenicity of the pancreatic ductal adenocarcinoma by negatively regulating frizzled-5" [Biochem. Biophys.… Co-author DOI 10.1016/j.bbrc.2019.01.086↗
  4. Krüppel-like factor 9 suppressed tumorigenicity of the pancreatic ductal adenocarcinoma by negatively regulating frizzled-5. Co-author DOI 10.1016/j.bbrc.2018.03.229↗
  5. Overexpression of S100A4 protein may be associated with the development and progression of pancreatic cancer. Co-author DOI 10.4103/0973-1482.172582↗
  6. KLF9 Is a Prognostic Indicator in Human Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.11756↗
  7. Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine. Last author DOI 10.1007/s13277-015-4044-4↗
  8. Secreted protein acidic and rich in cysteine inhibits the growth of human pancreatic cancer cells with G1 arrest induction. Co-author DOI 10.1007/s13277-014-2315-0↗
  9. [Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine]. Co-author PMID 25030587↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhengfa Mao · 6 shared papers, 2014–2019 · strength 0.44
  2. Xu‐Qing Wang · 6 shared papers, 2014–2019 · strength 0.44
  3. Weidong Jin · 2 shared papers, 2022–2024 · strength 0.41
  4. Zhonghu Li · 2 shared papers, 2022–2024 · strength 0.41
  5. Xin Fan · 4 shared papers, 2014–2018 · strength 0.28
  6. Bin Zhong · 1 shared paper, 2024 · strength 0.23
  7. Tao Zhang · 1 shared paper, 2024 · strength 0.23
  8. Peiyu Ji · 2 shared papers, 2018–2019 · strength 0.21
  9. Zhiyong Zhang · 1 shared paper, 2022 · strength 0.19
  10. Lei Cui · 2 shared papers, 2014–2016 · strength 0.10
  11. Yong Zhou · 1 shared paper, 2018 · strength 0.10
  12. Yuezhen Wu · 1 shared paper, 2018 · strength 0.10
  13. Yong Zhang · 1 shared paper, 2017 · strength 0.08
  14. Christoph W. Michalski · 1 shared paper, 2017 · strength 0.08
  15. Sheng-Chun Dang · 1 shared paper, 2016 · strength 0.06
  16. Ying Wang · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.